Phase 4 Lymphoma Trial, Recruiting (NCT07016165)

Phase 4 Lymphoma Trial, Recruiting NCT07016165 Sponsor: Gadjah Mada University Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT07016165 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children between 0 and 18 years old who have a blood cancer (such as leukaemia or lymphoma)
Children who have a blood cancer and develop a fever while having a low white blood cell count, specifically during certain treatment phases or disease types — this must be assessed and confirmed by a qualified paediatrician
A parent or guardian has given their agreement for the child to take part in the study

Who may not be able to join:

Children who have a blood cancer AND also have HIV infection or are in septic shock (a severe, life-threatening response to infection)
Children who have a known allergy to the antibiotics ciprofloxacin or ceftazidime
Children whose fever appears to be caused by a reaction to a blood transfusion
Children who have been receiving antibiotics in the 72 hours before joining the study — exceptions may apply for children already taking cotrimoxazole (to prevent a specific type of lung infection) or ciprofloxacin (as a preventive measure in certain blood cancers) (confirm with trial site)
Children who have significantly reduced kidney function or significantly reduced liver function, based on specific blood test results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +6281246572652

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07016165

Sponsor: Gadjah Mada University

Phase: Phase 4

Status: Recruiting

Condition: Lymphoma

Trial contact: +6281246572652

More information: https://clinicaltrials.gov/study/NCT07016165

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children between 0 and 18 years old who have a blood cancer (such as leukaemia or lymphoma)
Children who have a blood cancer and develop a fever while having a low white blood cell count, specifically during certain treatment phases or disease types — this must be assessed and confirmed by a qualified paediatrician
A parent or guardian has given their agreement for the child to take part in the study

Who may not be able to join:

Children who have a blood cancer AND also have HIV infection or are in septic shock (a severe, life-threatening response to infection)
Children who have a known allergy to the antibiotics ciprofloxacin or ceftazidime
Children whose fever appears to be caused by a reaction to a blood transfusion
Children who have been receiving antibiotics in the 72 hours before joining the study — exceptions may apply for children already taking cotrimoxazole (to prevent a specific type of lung infection) or ciprofloxacin (as a preventive measure in certain blood cancers) (confirm with trial site)
Children who have significantly reduced kidney function or significantly reduced liver function, based on specific blood test results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Gadjah Mada University

Registry

ClinicalTrials.gov

Start date

1 June 2025

Est. completion

30 November 2025

Where this trial is recruiting

🇮🇩 Indonesia

Primary endpoints

Duration of fever; Duration of Neutropenia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov